勃林格殷格翰启动三项针对难治性癌症的III期临床试验，加速精准肿瘤学研究-动脉网

Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers

CISION 等信源发布 2026-06-22 18:59



可切换为仅中文







Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment options

勃林格殷格翰致力于改善面临侵袭性癌症且目前治疗选择有限的患者的预后。

DAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig, Boehringer's immunoglobin G (IgG)-like bispecific T-cell engager, as a DLL3 biomarker-informed approach designed to help identify patients and inform treatment decisions for small cell lung cancer (SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC).

DAREON®-Lung-1 和 DAREON®-NEC-1 研究将评估 obrixtamig（勃林格殷格翰公司的一种免疫球蛋白 G [IgG] 样双特异性 T 细胞衔接器），作为一种基于 DLL3 生物标志物的策略，旨在帮助识别患者并为小细胞肺癌 (SCLC) 和肺外神经内分泌癌 (epNEC) 的治疗决策提供依据。

1,2

Beamion LUNG-3 will explore HERNEXEOS® (zongertinib tablets) in earlier stages of disease in resectable HER2 (

Beamion LUNG-3 研究将在疾病更早阶段探索 HERNEXEOS®（宗格替尼片）在可切除 HER2

ERBB2

)-mutant non-small cell lung cancer (NSCLC), where new targeted treatment options are still needed

）突变的非小细胞肺癌（NSCLC），目前仍需新的靶向治疗选择

RIDGEFIELD, Conn. and INGELHEIM, Germany

康涅狄格州里奇菲尔德和德国因格尔海姆

，

June 22, 2026

2026年6月22日

/PRNewswire/ -- Boehringer Ingelheim is advancing biomarker-informed approaches and extending precision care across multiple cancers and stages of disease, reinforcing its ambition to bring unprecedented impact and improve long-term outcomes where unmet need remains high.

/美通社/ -- 勃林格殷格翰正在推进基于生物标志物的方法，并将精准医疗扩展至多种癌症及疾病阶段，从而强化其雄心壮志，即在未满足需求依然较高的领域带来前所未有的影响并改善长期预后。

4,5,6

The company has initiated two Phase III clinical trials within the DAREON® program: DAREON®-Lung-1 in small cell lung cancer (SCLC) and DAREON®-NEC-1 in extrapulmonary neuroendocrine carcinoma (epNEC). In parallel, the Phase III Beamion LUNG-3 trial has been initiated in HER2 (

该公司已在DAREON®计划中启动两项III期临床试验：针对小细胞肺癌（SCLC）的DAREON®-Lung-1和针对肺外神经内分泌癌（epNEC）的DAREON®-NEC-1。与此同时，针对HER2（

ERBB2

)-mutant non-small cell lung cancer (NSCLC).

)突变型非小细胞肺癌（NSCLC）。

4,5,6

'People living with aggressive cancers often face a shortage of treatment choices,' said Lykke Hinsch Gylvin, MD, Chief Medical Officer, Boehringer Ingelheim. 'With the launch of these trials, we are advancing our precision oncology ambitions to move targeted therapies into earlier treatment lines and bring biomarker-informed science into late-stage development.

“患有侵袭性癌症的患者常常面临治疗选择匮乏的困境，”勃林格殷格翰首席医疗官Lykke Hinsch Gylvin医学博士表示。“随着这些临床试验的启动，我们正在推进精准肿瘤学战略，将靶向疗法前移至更早的治疗线数，并将基于生物标志物的科学研究引入后期开发阶段。”

By focusing on the biology of each tumor, we aim to give patients facing cancer more precise treatment options with the goal of improving outcomes where the need is greatest.'.

通过关注每种肿瘤的生物学特性，我们旨在为癌症患者提供更精准的治疗方案，以期在最需要的地方改善疗效。

Biomarker-informed approaches: DLL3

生物标志物指导的方法：DLL3

The two DAREON® Phase III trials mark a pivotal step for obrixtamig, Boehringer's investigational DLL3/CD3 T-cell engager, and for the company's broader biomarker strategy in aggressive neuroendocrine carcinomas (NECs) such as SCLC and epNEC. People with SCLC, the most aggressive type of lung cancer, often face short-lived therapeutic benefit and poor survival with existing approaches..

两项DAREON® III期临床试验标志着obrixtamig（勃林格殷格翰在研的DLL3/CD3 T细胞衔接器）的关键一步，也标志着该公司在侵袭性神经内分泌癌（NECs，如小细胞肺癌[SCLC]和肺外神经内分泌癌[epNEC]）更广泛的生物标志物战略的关键一步。小细胞肺癌是侵袭性最强的肺癌类型，患者采用现有疗法往往获益短暂且生存率低下。

5,7

EpNEC is a historically under-researched cancer for which survival outcomes have not improved in decades. For those living with these cancers, treatment options are limited and significant unmet needs persist.

EpNEC 是一种长期以来研究不足的癌症，其生存结局在数十年间未见改善。对于患有这些癌症的患者而言，治疗选择有限，且存在重大的未满足需求。

7,8

Delta-like canonical Notch ligand 3 (DLL3) is expressed on tumor cells in SCLC and epNEC while largely absent from non-cancerous cells. This makes it a potential predictive biomarker that could help to redefine treatment strategies for these aggressive cancers.

Delta样经典Notch配体3（DLL3）在小细胞肺癌（SCLC）和上皮性神经内分泌癌（epNEC）的肿瘤细胞中表达，而在非癌细胞中基本缺失。这使其成为一种潜在的预测性生物标志物，有助于重新定义这些侵袭性癌症的治疗策略。

9,10

DAREON®-Lung-1 and DAREON®-NEC-1 are designed to test whether the addition of obrixtamig, a DLL3 targeted T-cell engager, can improve outcomes in biomarker-informed patient populations versus the current standard of care.

DAREON®-Lung-1 和 DAREON®-NEC-1 旨在评估在生物标志物指导的患者人群中，与当前标准治疗相比，加用靶向 DLL3 的 T 细胞衔接器 obrixtamig 能否改善疗效结局。

1,2

Together, the studies aim to position obrixtamig as part of a broader shift toward more personalized and potentially more transformative treatment approaches in these aggressive NECs.

这些研究共同旨在将obrixtamig定位为更广泛转变的一部分，即在这些侵袭性神经内分泌癌（NECs）中转向更加个性化且可能更具变革性的治疗方案。

Precision oncology in earlier stages: HER2

早期阶段的精准肿瘤学：HER2

In addition, the company is investigating HERNEXEOS® (zongertinib tablets) in earlier stages of disease with the initiation of Beamion LUNG-3. This global, randomized Phase III trial will study the efficacy and safety of HERNEXEOS as adjuvant monotherapy compared with physician's choice standard of care in patients with stage II-IIIB HER2 (.

此外，随着Beamion LUNG-3研究的启动，该公司正在疾病更早阶段对HERNEXEOS®（宗格替尼片）进行研究。这项全球性、随机III期临床试验将评估HERNEXEOS作为辅助单药治疗与医生选择的标准治疗方案相比，在II至IIIB期HER2（

ERBB2

)-mutant NSCLC who have undergone complete surgical resection and have received either neoadjuvant or adjuvant therapy.

)-突变的非小细胞肺癌患者，这些患者已接受完全手术切除，并接受了新辅助或辅助治疗。

The study is designed to evaluate whether HERNEXEOS can improve disease-free survival compared to standard of care following surgery, addressing the significant risk of recurrence after curative-intent treatment.

本研究旨在评估与术后标准治疗相比，HERNEXEOS 是否能改善无病生存期，从而应对治愈性治疗后复发风险显著的问题。

十一

Beamion LUNG-3 reflects the company's focus on advancing targeted therapies earlier in the treatment pathway, where effective targeted adjuvant treatment options are not available.

Beamion LUNG-3 体现了公司致力于在缺乏有效靶向辅助治疗方案的治疗阶段，更早地推进靶向治疗。

This trial extends the investigation of zongertinib to early stage disease.

本试验将宗格替尼的研究扩展至早期疾病阶段。

Expanding the oncology portfolio

拓展肿瘤产品组合

Boehringer Ingelheim continues to expand its portfolio of precision oncology approaches that combine targeted therapies for biomarker-defined populations with innovative strategies to both activate and direct the immune system. This includes next-generation immunotherapies such as T-cell engagers, alongside complementary modalities that aim to enhance anti-tumor responses and address tumor-intrinsic drivers of disease.

勃林格殷格翰持续扩展其精准肿瘤治疗组合，将针对生物标志物定义人群的靶向疗法与激活和引导免疫系统的创新策略相结合。这包括下一代免疫疗法（如T细胞衔接器），以及旨在增强抗肿瘤反应并解决肿瘤内在疾病驱动因素的互补疗法。

By integrating these approaches, the company aims to expand treatment options for people facing cancers with high unmet medical need..

通过整合这些方法，公司旨在为面临高度未满足医疗需求的癌症患者扩大治疗选择。

About obrixtamig

关于 obrixtamig

Obrixtamig is an investigational novel Immunoglobin G (IgG)-like bispecific T-cell engager designed to bind concomitantly to DLL3 on tumor cells and CD3 on T-cells, potentially resulting in destruction of tumor cells by the body's own immune system. Obrixtamig is being evaluated in multiple, ongoing clinical trials, including a Phase I trial in combination with atezolizumab and chemotherapy in extensive-stage small-cell lung cancer (ES-SCLC) patients (DAREON®-8), a Phase Ib study to investigate obrixtamig in combination with the current SoC (carboplatin + etoposide) as 1L treatment for patients with DLL3-positive NEC, including epNEC (DAREON®-7), and a Phase II trial in patients with relapsed/refractory DLL3-high extrapulmonary neuroendocrine carcinomas (epNEC) (DAREON.

Obrixtamig 是一种在研的新型免疫球蛋白 G（IgG）样双特异性 T 细胞衔接器，旨在同时结合肿瘤细胞上的 DLL3 和 T 细胞上的 CD3，从而可能通过人体自身的免疫系统破坏肿瘤细胞。Obrixtamig 正在多项正在进行的临床试验中进行评估，包括一项在广泛期小细胞肺癌（ES-SCLC）患者中联合阿替利珠单抗和化疗的 I 期试验（DAREON®-8）、一项研究 Obrixtamig 联合当前标准治疗（卡铂 + 依托泊苷）作为 DLL3 阳性神经内分泌癌（NEC，包括肺外神经内分泌癌 [epNEC]）患者一线治疗的 Ib 期研究（DAREON®-7），以及一项针对复发性/难治性高表达 DLL3 的肺外神经内分泌癌（epNEC）患者的 II 期试验（DAREON）。

-5).

13,14,15

The Phase III clinical development program includes DAREON®-LUNG-1, which evaluates obrixtamig in combination with atezolizumab plus chemotherapy vs. atezolizumab plus chemotherapy for first-line use in patients with ES-SCLC.

III期临床开发项目包括DAREON®-LUNG-1，该研究评估obrixtamig联合阿替利珠单抗及化疗对比阿替利珠单抗联合化疗在广泛期小细胞肺癌（ES-SCLC）患者一线治疗中的疗效。

In addition, DAREON®-NEC-1 is evaluating obrixtamig in combination with current SoC (carboplatin and etoposide) vs. SoC alone as first-line therapy in patients with DLL3-positive unresectable locally advanced or metastatic epNEC.

此外，DAREON®-NEC-1 研究正在评估 obrixtamig 联合当前标准治疗（卡铂和依托泊苷）与单用标准治疗相比，作为 DLL3 阳性不可切除局部晚期或转移性肺外神经内分泌癌患者一线疗法的疗效。

In order to tackle hard-to-treat cancers, Boehringer is drawing on innovation enabled through collaboration. The company is developing obrixtamig through a long-term partnership with Oxford BioTherapeutics (OBT), using

为应对难治性癌症，勃林格殷格翰正借助通过合作实现的创新。该公司通过与牛津生物治疗公司（OBT）的长期合作伙伴关系，正在开发obrixtamig，利用

OBT's OGAP® platform

OBT 的 OGAP® 平台

to identify novel target opportunities for new immunotherapies harnessing its investigational T-cell engager, investigational cancer vaccine and exploratory oncolytic virus platforms.

以利用其研究中的T细胞衔接器、研究中的癌症疫苗和探索性溶瘤病毒平台，识别新的免疫疗法的新型靶点机会。

About HERNEXEOS® (zongertinib tablets)

关于 HERNEXEOS®（宗格替尼片）

HERNEXEOS® (zongertinib tablets) is an irreversible tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 (

HERNEXEOS®（宗格替尼片）是一种不可逆的酪氨酸激酶抑制剂（TKI），可选择性抑制HER2（

ERBB2

）。

十六

HERNEXEOS has been approved by the U.S. Food and Drug Administration (FDA) as the first orally administered, targeted therapy for adult patients with HER2 (

HERNEXEOS 已获美国食品药品监督管理局（FDA）批准，成为首款用于成人 HER2（

ERBB2)

ERBB2

-mutant advanced non-small cell lung cancer.

-突变型晚期非小细胞肺癌。

Comprehensive biomarker testing using next generation sequencing determines a patient's eligibility for treatment with HERNEXEOS by identifying HER2 (

通过下一代测序进行全面的生物标志物检测，通过识别HER2来确定患者是否适合接受HERNEXEOS治疗

ERBB2

)-mutant advanced NSCLC.

)-突变型晚期非小细胞肺癌。

16,17

The treatment is being evaluated in ongoing trials, across a range of earlier stages and advanced solid tumors with HER2 alterations. Beamion LUNG-2 is an ongoing Phase III controlled study evaluating HERNEXEOS as a first-line treatment for patients with advanced NSCLC that has HER2 tyrosine kinase domain mutations (.

该治疗方案正在多项正在进行中的临床试验中进行评估，涵盖携带HER2变异的早期至晚期多种实体瘤。Beamion LUNG-2是一项正在进行的III期对照研究，旨在评估HERNEXEOS作为一线治疗方案用于伴有HER2酪氨酸激酶结构域突变的晚期非小细胞肺癌（NSCLC）患者的疗效。

NCT06151574

）。

十八

Beamion LUNG-3 is a Phase III clinical trial investigating HERNEXEOS as an adjuvant monotherapy in patients with early-stage, resectable NSCLC (Stage II-IIIB) with HER2 (

Beamion LUNG-3 是一项 III 期临床试验，旨在评估 HERNEXEOS 作为辅助单药疗法在患有早期、可手术切除的非小细胞肺癌（II–IIIB 期）且 HER2（

ERBB2

)-mutations (

)突变(

NCT07195695

）。

About Boehringer Ingelheim in oncology

关于勃林格殷格翰在肿瘤学领域

We have a clear aspiration – to transform the lives of people facing cancer by delivering unprecedented impact, with the ultimate goal to redefine standards of care. Boehringer Ingelheim's long-term commitment to scientific innovation is reflected by the company's robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as in smart combinations of these approaches.

我们有一个明确的愿景——通过产生前所未有的影响，改变癌症患者的生活，最终目标是重新定义护理标准。勃林格殷格翰公司对科学创新的长期承诺体现在其强大的癌症细胞定向和免疫肿瘤学研究疗法管线中，以及这些方法的智能组合中。

In everything we do, we focus on people — not just data — working alongside them to develop solutions that truly meet their needs and help move cancer into the background of their lives. This drives our research approach, drawing on diverse minds and a long-term perspective to address the needs of people facing cancer today and for generations to come.

在我们所做的一切工作中，我们始终以人为核心，而不仅仅关注数据，通过与他们携手合作，开发真正满足其需求的解决方案，帮助癌症逐渐淡出他们的生活。这一理念驱动着我们的研究方法，汇聚多元智慧，秉持长远视角，以应对当今及未来世代面临癌症的人群的需求。

Read more at .

在 . 阅读更多内容。

https://www.boehringer-ingelheim.com/us/human-health/cancer

。

About Boehringer Ingelheim

关于勃林格殷格翰

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain.

勃林格殷格翰是一家专注于人类和动物健康的生物制药公司。作为行业内研发投入最高的企业之一，该公司致力于开发创新疗法，以改善和延长在存在高度未满足医疗需求领域的患者生命。自1885年成立以来，勃林格殷格翰始终保持独立，秉持长远视角，将可持续发展理念融入整个价值链。

Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at .

我们约54,300名员工服务于130多个市场，致力于构建一个更健康、更可持续的明天。了解更多请访问。

https://www.boehringer-ingelheim.com/us

。

What is HERNEXEOS (zongertinib tablets)?

什么是HERNEXEOS（宗格替尼片）？

HERNEXEOS is a prescription medicine used to treat adults with a type of lung cancer called non–squamous non–small cell lung cancer (NSCLC) that:

HERNEXEOS 是一种处方药，用于治疗患有非鳞状非小细胞肺癌（NSCLC）的成人患者，该药物适用于以下情况：

cannot be removed by surgery or that has spread to other parts of your body (metastatic), and

无法通过手术切除或已扩散至身体其他部位（转移性），且

has a certain mutation in the human epidermal growth factor receptor 2 (

在人表皮生长因子受体2（HER2）中存在某种突变

HER2

) gene

基因

Your healthcare provider will perform a test to make sure HERNEXEOS is right for you.

您的医疗保健提供者将进行一项检测，以确保 HERNEXEOS 适合您。

It is not known if HERNEXEOS is safe and effective in children.

目前尚不清楚 HERNEXEOS 在儿童中的安全性和有效性。

IMPORTANT SAFETY INFORMATION

重要安全信息

Before taking HERNEXEOS, tell your healthcare provider about all of your medical conditions, including if you:

在服用 HERNEXEOS 之前，请告知您的医疗保健提供者您所有的健康状况，包括是否：

have liver problems

有肝脏问题

have heart problems

有心脏问题

have lung or breathing problems other than lung cancer

患有除肺癌以外的肺部或呼吸系统疾病

are pregnant or plan to become pregnant. HERNEXEOS can harm your unborn baby

怀孕或计划怀孕。HERNEXEOS 可能对您的胎儿造成伤害

Females who are able to become pregnant:

能够怀孕的女性：

Your healthcare provider will do a pregnancy test before you start treatment with HERNEXEOS

在您开始接受 HERNEXEOS 治疗之前，您的医疗保健提供者将进行妊娠测试。

Use an effective form of birth control (contraception) during treatment with HERNEXEOS and for 2 weeks after your last dose

在使用 HERNEXEOS 治疗期间以及末次给药后 2 周内，应采取有效的避孕措施

Talk to your healthcare provider about birth control methods that might be right for you during this time

在此期间，请咨询您的医疗保健提供者，了解适合您的避孕方法。

Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with HERNEXEOS

如果在接受 HERNEXEOS 治疗期间怀孕或怀疑自己怀孕，请立即告知您的医疗保健提供者。

are breastfeeding or plan to breastfeed. It is not known if HERNEXEOS passes into your breastmilk. Do not breastfeed during treatment and for 2 weeks after your last dose of HERNEXEOS

正在哺乳或计划哺乳。目前尚不清楚 HERNEXEOS 是否会进入您的乳汁。在接受治疗期间以及末次服用 HERNEXEOS 后的 2 周内，请勿哺乳。

Tell your healthcare provider about all the medicines you take

告知您的医疗保健提供者您正在服用的所有药物

, including prescription and over-the-counter medicines, vitamins, and herbal supplements. HERNEXEOS may affect the way other medicines work, and other medicines may affect how HERNEXEOS works.

，包括处方药、非处方药、维生素和草本补充剂。HERNEXEOS 可能会影响其他药物的作用方式，而其他药物也可能会影响 HERNEXEOS 的作用方式。

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

了解您正在服用的药物。保留一份药物清单，在获取新药时出示给您的医疗保健提供者或药师。

What are the possible side effects of HERNEXEOS?

HERNEXEOS 的可能副作用有哪些？

HERNEXEOS may cause serious side effects, including:

HERNEXEOS 可能引起严重的副作用，包括：

liver problems.

肝脏问题。

Liver problems are common with HERNEXEOS and can be severe and life-threatening. Your healthcare provider will do blood tests to check your liver function before you start taking HERNEXEOS and during your treatment. Tell your healthcare provider right away if you develop any signs and symptoms of liver problems, including:.

使用 HERNEXEOS 期间常见肝脏问题，且可能严重甚至危及生命。在开始服用 HERNEXEOS 之前以及治疗期间，您的医疗保健提供者将进行血液检查以评估您的肝功能。如果您出现任何肝脏问题的体征和症状，包括：，请立即告知您的医疗保健提供者。

yellowing of your skin or the white part of your eyes (jaundice)

皮肤或眼白变黄（黄疸）

dark or brown (tea colored) urine

深色或棕色（茶色）尿液

pain on the upper right side of your stomach area (abdomen)

右上腹疼痛

bleeding or bruising more easily than normal

比平时更容易出血或出现瘀伤

feeling very tired

感到非常疲惫

loss of appetite

食欲减退

nausea or vomiting

恶心或呕吐

heart problems that may affect your heart's ability to pump blood.

可能影响心脏泵血功能的心脏问题。

HERNEXEOS can cause severe heart problems. Your healthcare provider will do tests to check your heart function before you start taking HERNEXEOS and during treatment. Tell your healthcare provider right away if you have any new or worsening symptoms of heart problems, including:

HERNEXEOS 可能导致严重的心脏问题。在开始服用 HERNEXEOS 之前以及治疗期间，您的医疗保健提供者会进行检查以评估您的心脏功能。如果您出现任何新的或加重的心脏问题症状，请立即告知您的医疗保健提供者，包括：

feeling like your heart is pounding or racing

感觉心脏剧烈跳动或加速

dizziness

头晕

tiredness

疲劳

feeling lightheaded

感到头晕

shortness of breath

呼吸短促

loss of consciousness

意识丧失

coughing

咳嗽

swelling of your legs, ankles, or feet

腿部、脚踝或足部肿胀

lung problems

肺部问题

. HERNEXEOS can cause lung problems that are severe or life-threatening. Tell your healthcare provider right away if you have any new or worsening symptoms of lung problems, including trouble breathing, shortness of breath, cough, or fever

. HERNEXEOS 可能导致严重或危及生命的肺部问题。如果您出现任何新的或加重的肺部问题症状，包括呼吸困难、气短、咳嗽或发热，请立即告知您的医疗保健提供者

Your healthcare provider may temporarily stop, decrease your dose, or permanently stop treatment with HERNEXEOS if you have serious side effects.

如果您出现严重副作用，您的医疗保健提供者可能会暂时停用、减少剂量或永久停止使用 HERNEXEOS 进行治疗。

The most common side effects of HERNEXEOS include:

HERNEXEOS 最常见的副作用包括：

diarrhea. HERNEXEOS can cause severe diarrhea. Tell your healthcare provider right away if you have new or worsening diarrhea

腹泻。HERNEXEOS 可能导致严重腹泻。如果您出现新的或加重的腹泻，请立即告知您的医疗保健提供者。

rash

皮疹

liver problems

肝脏问题

feeling tired

感到疲倦

nausea

恶心

muscle and joint pain

肌肉和关节疼痛

upper respiratory tract infection

上呼吸道感染

The most common severe abnormal blood tests include

最常见的严重异常血液检查包括

decreased white blood cell count, increased liver function tests, and decreased potassium levels.

白细胞计数减少，肝功能指标升高，钾水平降低。

HERNEXEOS may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

HERNEXEOS 可能导致女性和男性出现生育问题，从而影响您的生育能力。如果您对此有顾虑，请咨询您的医疗保健提供者。

These are not all of the possible side effects of HERNEXEOS. Call your doctor for medical advice about side effects. For more information, ask your healthcare provider or pharmacist.

以上并非 HERNEXEOS 所有可能的副作用。如有任何副作用相关的医疗建议，请咨询您的医生。如需更多信息，请向您的医疗保健提供者或药剂师咨询。

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit

我们鼓励您向美国食品药品监督管理局（FDA）报告处方药的不良反应。请访问

www.fda.gov/medwatch

or call 1-800-FDA-1088.

或拨打 1-800-FDA-1088。

CL-HER-100001 02.2026

CL-HER-100001 2026年2月

Please see full

请查看完整内容

Prescribing Information

处方信息

and

和

Patient Information

患者信息

。

MPR-US-104244

References:

参考文献：

ClinicalTrials.gov. DAREON-Lung-1 (

ClinicalTrials.gov. DAREON-Lung-1（

NCT07472517

). Accessed June 2026.

). 访问于2026年6月。

ClinicalTrials.gov. DAREON-NEC-1 (

ClinicalTrials.gov. DAREON-NEC-1（

NCT07544654

). Accessed June 2026.

). 访问于2026年6月。

ClinicalTrials.gov. Beamion LUNG-3 (

ClinicalTrials.gov. Beamion LUNG-3（

NCT07195695

). Accessed June 2026.

). 访问于2026年6月。

Xu J, Li Y, Xu B, Lian J, Lu H. Clinical characteristics and survival outcomes of extrapulmonary neuroendocrine carcinomas: a retrospective study.

徐杰，李燕，徐斌，连军，陆华。肺外神经内分泌癌的临床特征及生存结局：一项回顾性研究。

Front Endocrinol (Lausanne)

《前沿内分泌学》（洛桑）

. 2025;16:1635630. Published 2025 Oct 27. doi:10.3389/fendo.2025.1635630

. 2025;16:1635630. 发表于2025年10月27日。doi:10.3389/fendo.2025.1635630

Plaja A, et al. Small-Cell Lung Cancer Long-Term Survivor Patients : How to Find a Needle in a Haystack?. Int J Mol Sci. 2021;22(24):13508. Published 2021 Dec 16. doi:10.3390/ijms222413508

Plaja A 等. 小细胞肺癌长期生存者：如何在大海捞针？. 《国际分子科学杂志》. 2021;22(24):13508. 发表于 2021 年 12 月 16 日. doi:10.3390/ijms222413508

Jeon H, Wang S, Song J, Gill H, Cheng H. Update 2025: Management of Non Small-Cell Lung Cancer.

全 H，王 S，宋 J，吉尔 H，程 H。2025 年更新：非小细胞肺癌的管理。

Lung

肺

. 2025;203(1):53. Published 2025 Mar 25. doi:10.1007/s00408-025-00801-x

. 2025;203(1):53. 发表于2025年3月25日。doi:10.1007/s00408-025-00801-x

Uprety D, Seaton R, Niroula A, Hadid T, Parikh K, Ruterbusch JJ. Trends in the incidence and survival outcomes in patients with small cell lung cancer in the United States: an analysis of the SEER database. Cancer Med. 2025;14(3):e70608. doi:10.1002/cam4.70608

Uprety D, Seaton R, Niroula A, Hadid T, Parikh K, Ruterbusch JJ. 美国小细胞肺癌患者发病率和生存结局的趋势：基于SEER数据库的分析. Cancer Med. 2025;14(3):e70608. doi:10.1002/cam4.70608

Frizziero M, Chakrabarty B, Nagy B, et al. Is the morphological subtype of extra-pulmonary poorly differentiated neuroendocrine carcinoma clinically relevant? Cancers (Basel). 2021;13(16):3986

Frizziero M, Chakrabarty B, Nagy B, 等. 肺外低分化神经内分泌癌的形态学亚型是否具有临床意义？《癌症》（巴塞尔）. 2021;13(16):3986

Liverani C, Bongiovanni A, Mercatali L, et al. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Pathol. 2021;32(2):309-317. doi:10.1007/s12022-020-09657-81

Liverani C, Bongiovanni A, Mercatali L, 等. DLL3表达在胃肠胰神经内分泌肿瘤中的诊断和预测作用. Endocr Pathol. 2021;32(2):309-317. doi:10.1007/s12022-020-09657-8

Wermke M, et al. Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. J Clin Oncol 2025;43(27):3021–31.

Wermke M 等. Delta 样配体 3/CD3 IgG 样 T 细胞衔接器 Obrixtamig (BI 764532) 在 Delta 样配体 3+ 小细胞肺癌或神经内分泌癌患者中的 I 期剂量递增结果. 《临床肿瘤学杂志》2025;43(27):3021–31.

Brandon, S. et al. Risk factors and survival associated with lung cancer recurrence after curative-intent surgery: beyond TNM pathological staging. Journal Of Thoracic Disease. 2025;17(11):10285-10297.

Brandon, S. 等. 根治性手术后肺癌复发的危险因素及生存情况：超越 TNM 病理分期. 《胸科疾病杂志》. 2025;17(11):10285-10297.

Hao S, Zhao S, Shi L, Zhong L, Wei H, Jiao X, Xue C. Targeting rare oncogenic mutations in resectable non-small cell lung cancer: emerging perioperative strategies. Journal of Thoracic Disease. 2026;18(2)

郝 S，赵 S，石 L，钟 L，魏 H，焦 X，薛 C。靶向可切除非小细胞肺癌中的罕见致癌突变：新兴的围手术期策略。《胸科疾病杂志》. 2026;18(2)

Peters, S, et al. DAREON®-8: updated efficacy and safety from a phase I dose-escalation/expansion trial of first-line (1L) obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC). Poster presented at: American Society of Clinical Oncology Annual Meeting; May 29 – June 2, 2026; Chicago, IL..

Peters S 等. DAREON®-8：一线（1L）obrixtamig 联合化疗及阿替利珠单抗治疗广泛期小细胞肺癌（ES-SCLC）的 I 期剂量递增/扩展试验的最新疗效和安全性数据。海报展示于：美国临床肿瘤学会年会；2026年5月29日至6月2日；伊利诺伊州芝加哥。

ClinicalTrials.gov. DAREON-7 (

ClinicalTrials.gov. DAREON-7（

NCT06132113

). Accessed June 2026.

）。访问于2026年6月。

ClinicalTrials.gov. DAREON-5 (

ClinicalTrials.gov. DAREON-5（

NCT05882058

). Accessed June 2026.

）。访问于2026年6月。

HERNEXEOS Prescribing Information.